González L, Sánchez MA, Insausti CL

Language: Spanish
References: 16
Page: 165-171
PDF size: 186.26 Kb.

ABSTRACT

Background: Sickle cell anemia is a public health problem in Venezuela due to high morbidity in children.
Objective: To evaluate hydroxyurea (HU) treatment response in children with sickle cell disease.
Materials and methods: A descriptive analytical study among 16 sickle cell anemia disease children aged 6 months - 18 years. Initial HU dose was 10mg/kg/d. prepared as syrup at mean concentration of 100mg/mL.
Results: The number of painful crises decreased to <3 in 87% of patients (p = 0.001). None of the patients had acute thoracic syndrome or splenic sequestration crisis. Of patients, 71% had no infections after the first year of treatment. The hospital incomes decreased from 93 to 36%, and 64% did not need hospitalization (p = 0.031). The transfusion requirement decreased from 23% to 2% (p = 0.032). No changes in hematologic parameters or adverse reactions were observed. The maximum dose of HU was 25 mg/kg/day in 28.6% of patients.
Conclusions: The preliminary results obtained in this group of patients would ratify that HU represent a good treatment option to decrease the sickle cell anemia morbidity.

REFERENCES

1. Embury Sthephen, Hoffman Hematology: Basic Principles and Practice. 3rd ed. Philadelphia, Pennsylvania: Churchill Livingstone, 2005; 510-705.

2. Wong WC. Wintrobe´s Hematology. 11th ed. Lippincott Williams & Wilkins Publisher; 2003. p.1032-1072.

3. Salazar L. Raquel. La hemoglobina S en la población Venezolana. Invest Clín 2004; 45(2):175-183.

4. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in sickle cell anemia. NEJM 1995; 322: 1317-1322

5. Ferster L, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001; 97(11): 3628-3632.

6. Wang WC, Helms RW, Lynn HS, et al. Effect of Hydroxyurea on growth of children with sickle cell anemia: Results of the HUG-KIDS study. J Pediatr 2002;140(2): 225-229.

7. Hankins J, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 2005;106(7): 2269-2274.

8. ClinicalTrials.gov [database on the internet]. Bethesda (MD): National Institute of Health. [cited 2008 Oct 14]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00006400 (N. del T.: En español: [base de datos en Internet]. [citado 14 Oct 2008].

9. Cokic VP, Andri SA, Stojilkovic SS, et al. Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood 2008;111(3):1117-1122

10. Ryan K, Heeney M. Use of hydroxyurea in pediatric patients with sickle cell disease. NEPSCC May 2004; 1-5.

11. Singh H, Dulhani N, Nel Kumar B, et al. Effective control of sickle cell disease with hydroxyurea therapy. Indian J of Pharmacol 2010;42:32-35.

12. Rogers Zora R. Spleen function in infants with sickle cell anemia: Baseline data from the BABY HUG trial. 50th ASH Annual Meeting and Exposition, Online Program and Abstracts Jan 2009; Poster Board I-521.

13. Lanzkron S, Haywood C Jr. Hospitalization rates and costs of care of patients with sickle cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematology 2006;81(12): 927-932.

14. Akar NA, Adekile A. Ten-year review of hospital admissions among children with sickle cell disease in Kuwait. Medical Princ Prac 2008;17:404-408.

15. Sileman H, Wali Y, Al Saadoon M, et al. Hydroxyurea or chronic exchange transfusions in patients with sickle cell disease: role of transcranial Doppler ultrasound in stroke prophylaxis. J Pediatr Hematol Oncol 2009;31(1):42-44.

16. Zimmerman S, Schultz W. Sustained long-term hematologic efficacy of hydroxyurea at máximum tolerated dose in children with sickle cell disease. Blood 2004;103(6):2039-2046.